Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 7 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Inovio Pharmaceuticals Inc. currently manages 14 pending office actions within the Biotechnology & Pharmaceuticals technology area. This volume of activity is spread across 14 distinct examiners, which suggests that the company is interacting with a wide variety of individual perspectives at the patent office. Such a distribution ensures that no individual examiner's specific tendencies dominate the overall prosecution of the portfolio.
The active matters are situated within 6 distinct art units, reflecting a diverse range of technical focuses within the biotechnology field. ZAMORY, JUSTIN L is the busiest examiner for the portfolio, currently overseeing 1 pending office action. This examiner's workload represents a portion of the 14 pending office actions, illustrating a decentralized approach where prosecution responsibilities are fragmented across the various art units and examiners involved. This fragmentation may require the company to coordinate across multiple examiner interviews and responses simultaneously.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (14%) |
| §103 only | 3 (21%) |
| §102 only | 1 (7%) |
| §112 only | 1 (7%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 3 (21%) |
| Multi-statute (no §101) | 3 (21%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZAMORY, JUSTIN L | 1 | 72.9% | +17.4% |
| ALLEN, MICHAEL D | 1 | 32.0% | +49.4% |
| ZOU, NIANXIANG | 1 | 64.1% | +24.8% |
| HILL, MYRON G | 1 | 66.2% | +20.6% |
| FARRAR, LAUREN PENG | 1 | 78.6% | +15.5% |
| GILL, RACHEL B | 1 | 65.6% | +28.3% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.4% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| PARKIN, JEFFREY S | 1 | 63.7% | +21.7% |
| HENZE, DAVID V | 1 | 69.7% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18493133 | LASSA VIRUS VACCINE AND USES THEREOF | GILL, RACHEL B | 34d |
| 18648280 | KINETIC VACUUM TREATMENT DEVICES, SYSTEMS, AND METHODS | ZAMORY, JUSTIN L | — |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | HILL, MYRON G | — |
| 18300588 | Methods Of Treatment Of High Grade Squamous Intraepithelial Lesion (HSIL) | ALAM, DANYAL HASSAN | — |
| 18174298 | Handheld Electroporation Devices, And Related Systems And Methods | HENZE, DAVID V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18503487 | Vaccines For Human Papilloma Virus And Methods For Using The Same | ZOU, NIANXIANG | 138d overdue |
| 18493133 | LASSA VIRUS VACCINE AND USES THEREOF | GILL, RACHEL B | 34d |
| 18648280 | KINETIC VACUUM TREATMENT DEVICES, SYSTEMS, AND METHODS | ZAMORY, JUSTIN L | — |
| 18593320 | METHODS OF TREATMENT OF HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) | ALLEN, MICHAEL D | — |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | HILL, MYRON G | — |
| 18493512 | Vacuum-Assisted Agent Delivery Devices, and Related Systems and Methods | FARRAR, LAUREN PENG | — |
| 18486708 | Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same | KINSEY WHITE, NICOLE ERIN | — |
| 18300973 | Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use | PARKIN, JEFFREY S | — |
| Art Unit | Apps |
|---|---|
| 1671 | 5 |
| 3783 | 2 |
| 1672 | 2 |
| 2859 | 1 |
| 1619 | 1 |
| 1643 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18648280 | KINETIC VACUUM TREATMENT DEVICES, SYSTEMS, AND METHODS | ZAMORY, JUSTIN L | — | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18593320 | METHODS OF TREATMENT OF HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) | ALLEN, MICHAEL D | 1671 | §102§103§112DP | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18503487 | Vaccines For Human Papilloma Virus And Methods For Using The Same | ZOU, NIANXIANG | 1671 | DP | Non-Final OA | 138d overdue | Pending | Nov 07, 2023 |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | HILL, MYRON G | 1671 | §101§103 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18493512 | Vacuum-Assisted Agent Delivery Devices, and Related Systems and Methods | FARRAR, LAUREN PENG | 3783 | §103 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18493133 | LASSA VIRUS VACCINE AND USES THEREOF | GILL, RACHEL B | 1671 | §102§103§112Other | Non-Final OA | 34d | Pending | Oct 24, 2023 |
| 18486708 | Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same | KINSEY WHITE, NICOLE ERIN | 1672 | §103§112DP | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18300588 | Methods Of Treatment Of High Grade Squamous Intraepithelial Lesion (HSIL) | ALAM, DANYAL HASSAN | 1672 | §101§103 | Final Rejection | — | Pending | Apr 14, 2023 |
| 18300973 | Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use | PARKIN, JEFFREY S | 1671 | §112 | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18174298 | Handheld Electroporation Devices, And Related Systems And Methods | HENZE, DAVID V | 2859 | §102§103 | Non-Final OA | — | Pending | Feb 24, 2023 |
| 18045575 | TERT IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME | ALAWADI, SARAH | 1619 | §102Other | Final Rejection | 34d | Pending | Oct 11, 2022 |
| 17474389 | Checkpoint Inhibitor and Vaccine Combinations and Use of Same for Immunotherapy | NATARAJAN, MEERA | 1643 | §103DP | Final Rejection | 15d overdue | Pending | Sep 14, 2021 |
| 17063977 | PD1 AND PDL1 ANTIBODIES AND VACCINE COMBINATIONS AND USE OF SAME FOR IMMUNOTHERAPY | HINES, JANA A | 1645 | §103 | Non-Final OA | 15d | Pending | Oct 06, 2020 |
| 16804707 | VARIABLE CURRENT DENSITY SINGLE NEEDLE ELECTROPORATION SYSTEM AND METHOD | VU, QUYNH-NHU HOANG | 3783 | §103 | Final Rejection | 37d overdue | Pending | Feb 28, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial